Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

M Ventures

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 99
Average round size
info
The average size of a deal this fund participated in
$26M
Portfolio companies 68
Rounds per year 7.07
Lead investments 25
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.31
Exits 8
Key employees 12
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

In 2017 was created M Ventures, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the Menlo Park.

This organization was formed by Adrian Fenty, Alyson DeNardo, Mike Palank. Besides them, we counted 10 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the M Ventures, startups are often financed by 5AM Ventures, Versant Ventures, SV Angel. The meaningful sponsors for the fund in investment in the same round are Y Combinator, SR One, Novo Seeds. In the next rounds fund is usually obtained by Y Combinator, SR One, Novo Seeds.

The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight WITHIN (VR/AR), Anaphore, DNA Script. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Software, eSports.

When the investment is from M Ventures the average startup value is 10-50 millions dollars. The fund is constantly included in 7-12 deals per year. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018. This M Ventures works on 28 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of M Ventures:
Typical Co-investors
M Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after M Ventures:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Storm Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$30M14 Dec 2022 Cambridge, England, United Kingdom

Sonde Health

Biotechnology
Health Care
$19M08 Dec 2022 Boston, Massachusetts, United States

Nucleome Therapeutics

3D Technology
Biotechnology
Health Care
Therapeutics
$51M19 Oct 2022 Oxford, England, United Kingdom

Metalenz

3D Technology
Consumer Electronics
Manufacturing
Semiconductor
Sensor
$30M05 Oct 2022 Boston, Massachusetts, United States

NeoLogic (VLSI)

Electronics
Semiconductor
$2M03 Aug 2022 Netanya, HaMerkaz, Israel

Pictor Labs

Artificial Intelligence
Health Care
$15M26 May 2022 Los Angeles, California, United States

Altoida, Inc.

Application Software
Augmented Reality
Diagnostic Equipment
Health Care
Health Diagnostics
Medical
Medical Device
mHealth
Other Healthcare Technology Systems
Software
$14M30 Mar 2022 Washington, District of Columbia, United States

Concerto Biosciences

Biotechnology
Life Science
Medical
$24M22 Mar 2022 Cambridge, Massachusetts, United States

Plexium

Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
$102M23 Feb 2022 San Diego, California, United States
News
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Theolytics Expands Series A Funding Round

– Theolytics, an Oxford, UK-based developer of a library of potential adenovirus product candidates and breakthrough bioselection systems, raised new funding from M Ventures.
– Funding was joined by Epidarex Capital and Taiho Ventures in an extension to the Series A financing.
– The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company’s technology platforms.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent M Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: